Treatment of inflammatory myopathies

被引:0
作者
Mastaglia, FL
Phillips, BA
Zilko, P
机构
[1] QUEEN ELIZABETH II MED CTR,DEPT MED,PERTH,WA 6009,AUSTRALIA
[2] QUEEN ELIZABETH II MED CTR,DEPT NEUROL,PERTH,WA 6009,AUSTRALIA
[3] QUEEN ELIZABETH II MED CTR,DEPT CLIN IMMUNOL,PERTH,WA 6009,AUSTRALIA
关键词
inflammatory myopathies; treatment; polymyositis; dermatomyositis; inclusion body myositis;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The treatment of the immune-mediated inflammatory myopathies remains largely empirical. Corticosteroids are usually effective in polymyositis and dermatomyositis but may need to be combined with methotrexate or azathioprine in some patients, Intravenous immunoglobulin (IVIg) is effective as add-on therapy in some patients not adequately controlled with steroids or immunosuppressive agents, but further controlled trials of IVIg are necessary to define the indications and optimal dose regimens. Cyclophosphamide, cyclosporin, or chlorambucil may be effective in patients with refractory polymyositis or dermatomyositis. Low-dose whole body or lymphoid irradiation is a last option in severely disabled patients resistant to all other treatments. As a small proportion of patients with inclusion body myositis respond to corticosteroid or immunosuppressive therapy, a 3-6-month trial of such therapy is justified in this condition. More specific immunotherapy for these disorders awaits identification of the target antigens and further clarification of the immunopathogenetic mechanisms. (C) 1997 John Wiley & Sons, Inc.
引用
收藏
页码:651 / 664
页数:14
相关论文
共 50 条
  • [31] The possible role of physical exercise on the treatment of idiopathic inflammatory myopathies
    Painelli, Vitor de Salles
    Gualano, Bruno
    Artioli, Guilherme Giannini
    de Sa Pinto, Ana Lucia
    Bonfa, Eloisa
    Lancha Junior, Antonio Herbert
    Lima, Fernanda Rodrigues
    AUTOIMMUNITY REVIEWS, 2009, 8 (05) : 355 - 359
  • [32] Importance of inflammatory myopathies
    Pongratz, D
    SCHMERZ, 2003, 17 (06): : 432 - +
  • [33] Idiopathic inflammatory myopathies
    Limaye, V. S.
    Blumbergs, P.
    Roberts-Thomson, P. J.
    INTERNAL MEDICINE JOURNAL, 2009, 39 (03) : 179 - 190
  • [34] Incidence and prevalence of inflammatory myopathies: a systematic review
    Meyer, Alain
    Meyer, Nicolas
    Schaeffer, Mickael
    Gottenberg, Jacques-Eric
    Geny, Bernard
    Sibilia, Jean
    RHEUMATOLOGY, 2015, 54 (01) : 50 - 63
  • [35] Recent clinical trials in idiopathic inflammatory myopathies
    Leclair, Valerie
    Lundberg, Ingrid E.
    CURRENT OPINION IN RHEUMATOLOGY, 2017, 29 (06) : 652 - 659
  • [36] Rituximab treatment in patients with refractory inflammatory myopathies
    Mahler, Elien A. M.
    Blom, Marlies
    Voermans, Nicol C.
    van Engelen, Baziel G. M.
    van Riel, Piet L. C. M.
    Vonk, Madelon C.
    RHEUMATOLOGY, 2011, 50 (12) : 2206 - 2213
  • [37] Evaluation and treatment of inflammatory myopathies
    Amato, A. A.
    Barohn, R. J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (10) : 1060 - 1068
  • [38] Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy
    Kamiya, Mari
    Kimura, Naoki
    Umezawa, Natsuka
    Hasegawa, Hisanori
    Yasuda, Shinsuke
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [39] Biologics for idiopathic inflammatory myopathies
    Moghadam-Kia, Siamak
    Aggarwal, Rohit
    Oddis, Chester V.
    CURRENT OPINION IN RHEUMATOLOGY, 2017, 29 (06) : 645 - 651
  • [40] Inflammatory myopathies: diagnosis and classifications
    Dimitri, Dalia
    PRESSE MEDICALE, 2009, 38 (7-8): : 1141 - 1163